Cargando…

Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019

BACKGROUND AND AIM: Circulating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Feng, Zheng, Kenneth I., Yan, Hua-Dong, Sun, Qing-Feng, Pan, Ke-Hua, Wang, Ting-Yao, Chen, Yong-Ping, Targher, Giovanni, Byrne, Christopher D., George, Jacob, Zheng, Ming-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982673/
https://www.ncbi.nlm.nih.gov/pubmed/33763027
http://dx.doi.org/10.3389/fendo.2021.604100
_version_ 1783667771833319424
author Gao, Feng
Zheng, Kenneth I.
Yan, Hua-Dong
Sun, Qing-Feng
Pan, Ke-Hua
Wang, Ting-Yao
Chen, Yong-Ping
Targher, Giovanni
Byrne, Christopher D.
George, Jacob
Zheng, Ming-Hua
author_facet Gao, Feng
Zheng, Kenneth I.
Yan, Hua-Dong
Sun, Qing-Feng
Pan, Ke-Hua
Wang, Ting-Yao
Chen, Yong-Ping
Targher, Giovanni
Byrne, Christopher D.
George, Jacob
Zheng, Ming-Hua
author_sort Gao, Feng
collection PubMed
description BACKGROUND AND AIM: Circulating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to describe the association between circulating IL-6 levels and MAFLD at hospital admission with risk of severe COVID-19. METHODS: A total of 167 patients with laboratory-confirmed COVID-19 from three Chinese hospitals were enrolled. Circulating levels of IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured at admission. All patients were screened for fatty liver by computed tomography. Forty-six patients were diagnosed as MAFLD. RESULTS: Patients with MAFLD (n = 46) had higher serum IL-6 levels (median 7.1 [interquartile range, 4.3–20.0] vs. 4.8 [2.6–11.6] pg/mL, p = 0.030) compared to their counterparts without MAFLD (n = 121). After adjustment for age and sex, patients with MAFLD had a ~2.6-fold higher risk of having severe COVID-19 than those without MAFLD. After adjustment for age, sex and metabolic co-morbidities, increased serum IL-6 levels remained associated with higher risk of severe COVID-19, especially among infected patients with MAFLD (adjusted-odds ratio 1.14, 95% CI 1.05–1.23; p = 0.002). There was a significant interaction effect between serum IL-6 levels and MAFLD for risk of severe COVID-19 (p for interaction = 0.008). CONCLUSIONS: Patients with MAFLD and elevated serum IL-6 levels at admission are at higher risk for severe illness from COVID-19.
format Online
Article
Text
id pubmed-7982673
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79826732021-03-23 Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019 Gao, Feng Zheng, Kenneth I. Yan, Hua-Dong Sun, Qing-Feng Pan, Ke-Hua Wang, Ting-Yao Chen, Yong-Ping Targher, Giovanni Byrne, Christopher D. George, Jacob Zheng, Ming-Hua Front Endocrinol (Lausanne) Endocrinology BACKGROUND AND AIM: Circulating levels of interleukin (IL)-6, a well-known inflammatory cytokine, are often elevated in coronavirus disease-2019 (COVID-19). Elevated IL-6 levels are also observed in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Our study aimed to describe the association between circulating IL-6 levels and MAFLD at hospital admission with risk of severe COVID-19. METHODS: A total of 167 patients with laboratory-confirmed COVID-19 from three Chinese hospitals were enrolled. Circulating levels of IL-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ were measured at admission. All patients were screened for fatty liver by computed tomography. Forty-six patients were diagnosed as MAFLD. RESULTS: Patients with MAFLD (n = 46) had higher serum IL-6 levels (median 7.1 [interquartile range, 4.3–20.0] vs. 4.8 [2.6–11.6] pg/mL, p = 0.030) compared to their counterparts without MAFLD (n = 121). After adjustment for age and sex, patients with MAFLD had a ~2.6-fold higher risk of having severe COVID-19 than those without MAFLD. After adjustment for age, sex and metabolic co-morbidities, increased serum IL-6 levels remained associated with higher risk of severe COVID-19, especially among infected patients with MAFLD (adjusted-odds ratio 1.14, 95% CI 1.05–1.23; p = 0.002). There was a significant interaction effect between serum IL-6 levels and MAFLD for risk of severe COVID-19 (p for interaction = 0.008). CONCLUSIONS: Patients with MAFLD and elevated serum IL-6 levels at admission are at higher risk for severe illness from COVID-19. Frontiers Media S.A. 2021-03-08 /pmc/articles/PMC7982673/ /pubmed/33763027 http://dx.doi.org/10.3389/fendo.2021.604100 Text en Copyright © 2021 Gao, Zheng, Yan, Sun, Pan, Wang, Chen, Targher, Byrne, George and Zheng http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Gao, Feng
Zheng, Kenneth I.
Yan, Hua-Dong
Sun, Qing-Feng
Pan, Ke-Hua
Wang, Ting-Yao
Chen, Yong-Ping
Targher, Giovanni
Byrne, Christopher D.
George, Jacob
Zheng, Ming-Hua
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title_full Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title_fullStr Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title_full_unstemmed Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title_short Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
title_sort association and interaction between serum interleukin-6 levels and metabolic dysfunction-associated fatty liver disease in patients with severe coronavirus disease 2019
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982673/
https://www.ncbi.nlm.nih.gov/pubmed/33763027
http://dx.doi.org/10.3389/fendo.2021.604100
work_keys_str_mv AT gaofeng associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT zhengkennethi associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT yanhuadong associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT sunqingfeng associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT pankehua associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT wangtingyao associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT chenyongping associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT targhergiovanni associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT byrnechristopherd associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT georgejacob associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019
AT zhengminghua associationandinteractionbetweenseruminterleukin6levelsandmetabolicdysfunctionassociatedfattyliverdiseaseinpatientswithseverecoronavirusdisease2019